Literature DB >> 3336776

Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers.

S H Weiss1, J J Goedert, S Gartner, M Popovic, D Waters, P Markham, F di Marzo Veronese, M H Gail, W E Barkley, J Gibbons.   

Abstract

In a prospective cohort study of 265 laboratory and affiliated workers, one individual with no recognized risk factors for human immunodeficiency virus type 1 (HIV-1) infection was HIV-1 seropositive at the time of entry into the study. Molecular analyses of two HIV-1 isolates derived in two independent laboratories from a blood sample from this worker showed that the isolates were indistinguishable from a genotypic form of HIV-1 present in the H9/HTLV-IIIB cell line. Exposure to this strain of virus most probably occurred during work with concentrated virus or culture fluids from virus-producing cell lines under standard Biosafety Level 3 containment. Although no specific incident leading to this infection has been identified, undetected skin contact with virus culture supernatant might have occurred. This worker was the only one found to be positive among the subgroup of 99 workers who shared a work environment involving exposure to concentrated virus. The incidence rate of 0.48 per 100 person-years exposure indicates that prolonged laboratory exposure to concentrated virus is associated with some risk of HIV-1 infection, which is comparable to the risk for health care workers experiencing a needle stick exposure. While none of the ten workers with parenteral exposure to HIV-1 in this cohort became infected, a worker in another laboratory did seroconvert following an injury with a potentially contaminated needle. Strict Biosafety Level 3 containment and practices should be followed when working with concentrated HIV-1 preparations, and further refinement of the procedures may be necessary.

Entities:  

Mesh:

Year:  1988        PMID: 3336776     DOI: 10.1126/science.3336776

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  43 in total

1.  Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.

Authors:  T Beaumont; S Broersen; A van Nuenen; H G Huisman; A M de Roda Husman; J L Heeney; H Schuitemaker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 2.  Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation.

Authors:  Jason L Dehart; Vicente Planelles
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

Review 3.  HIV-1 Vpr: mechanisms of G2 arrest and apoptosis.

Authors:  Joshua L Andersen; Erwann Le Rouzic; Vicente Planelles
Journal:  Exp Mol Pathol       Date:  2008-04-25       Impact factor: 3.362

4.  Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.

Authors:  S H Pincus; K G Messer; P L Nara; W A Blattner; G Colclough; M Reitz
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

5.  Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1.

Authors:  N V Sipsas; S A Kalams; A Trocha; S He; W A Blattner; B D Walker; R P Johnson
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

6.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Authors:  S H Pincus; K G Messer; D H Schwartz; G K Lewis; B S Graham; W A Blattner; G Fisher
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

7.  Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.

Authors:  L Q Zhang; P MacKenzie; A Cleland; E C Holmes; A J Brown; P Simmonds
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

8.  Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.

Authors:  N L Michael; J A Nelson; V N KewalRamani; G Chang; S J O'Brien; J R Mascola; B Volsky; M Louder; G C White; D R Littman; R Swanstrom; T R O'Brien
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 9.  Estimating per-act HIV transmission risk: a systematic review.

Authors:  Pragna Patel; Craig B Borkowf; John T Brooks; Arielle Lasry; Amy Lansky; Jonathan Mermin
Journal:  AIDS       Date:  2014-06-19       Impact factor: 4.177

10.  Occupational exposures to blood and risk of HIV transmission in a general hospital (1986-88).

Authors:  V Puro; M Ranchino; F Profili
Journal:  Eur J Epidemiol       Date:  1990-03       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.